Anti-androgens hydroxyflutamide and bicalutamide have been used over many years in prostate cancer treatment, and the studies on resistance mechanisms were particularly focused on AR mutations which emerge during endocrine therapy with these compounds. This evidence concerns the gene AR and Familial prostate cancer.